Research ArticleClinical Studies

Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer

AKIRA TAKEUCHI, TETSUYA OGURI, SATOSHI FUKUDA, KAZUKI SONE, YUSUKE KAGAWA, TAKEHIRO UEMURA, OSAMU TAKAKUWA, KEN MAENO, KENSUKE FUKUMITSU, YOSHIHIRO KANEMITSU, TOMOKO TAJIRI, HIROTSUGU OHKUBO, MASAYA TAKEMURA, YUTAKA ITO and AKIO NIIMI
Anticancer Research August 2020, 40 (8) 4245-4251; DOI: https://doi.org/10.21873/anticanres.14426

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Progression-free survival according to the dominant model of the solute carrier family 22 member 16 rs714368 single nucleotide polymorphism. These data were analyzed by Kaplan–Meier methods and compared using the log-rank test.

Tables

  • Table I.
  • Table II.
  • Table III.
  • Table IV.
  • Table V.
  • Table VI.
  • Table VII.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer
AKIRA TAKEUCHI, TETSUYA OGURI, SATOSHI FUKUDA, KAZUKI SONE, YUSUKE KAGAWA, TAKEHIRO UEMURA, OSAMU TAKAKUWA, KEN MAENO, KENSUKE FUKUMITSU, YOSHIHIRO KANEMITSU, TOMOKO TAJIRI, HIROTSUGU OHKUBO, MASAYA TAKEMURA, YUTAKA ITO, AKIO NIIMI
Anticancer Research Aug 2020, 40 (8) 4245-4251; DOI: 10.21873/anticanres.14426
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords